EP3805404 - GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 09.06.2023 Database last updated on 31.08.2024 | |
Former | Request for examination was made Status updated on 22.10.2021 | ||
Former | The application has been published Status updated on 12.03.2021 | Most recent event Tooltip | 28.05.2024 | New entry: Renewal fee paid | Applicant(s) | For all designated states Board of Regents, The University of Texas System 210 West 7th Street Austin, TX 78701 / US | For all designated states Guardant Health, Inc. 3100 Hanover Street Palo Alto, CA 94304 / US | [2024/14] |
Former [2021/15] | For all designated states Board of Regents, The University of Texas System 210 West 7th Street Austin, TX 78701 / US | ||
For all designated states Guardant Health, Inc. 505 Penobscot Drive Redwood City, CA 94063 / US | Inventor(s) | 01 /
KOPETZ, Scott 201 West 7th Street Suite 820 Austin, TX 78701 / US | 02 /
TALASAZ, AmirAli 2181 Camino A Los Cerros Menlo Park, CA 94025 / US | [2021/15] | Representative(s) | Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | [N/P] |
Former [2021/15] | Marshall, Cameron John Carpmaels & Ransford LLP One Southampton Row London WC1B 5HA / GB | Application number, filing date | 20209515.4 | 13.05.2015 | [2021/15] | Priority number, date | US201461992877P | 13.05.2014 Original published format: US 201461992877 P | US201462004749P | 29.05.2014 Original published format: US 201462004749 P | [2021/15] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP3805404 | Date: | 14.04.2021 | Language: | EN | [2021/15] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 12.03.2021 | Classification | IPC: | C12Q1/68, A61K39/395, C07K14/71 | [2021/15] | CPC: |
C12Q1/6886 (EP,US);
C07K14/71 (EP,US);
C07K14/82 (EP,US);
C07K16/2863 (EP,US);
C07K16/30 (EP,US);
G16B20/10 (EP,US);
G16B20/20 (EP,US);
G16B99/00 (EP,US);
A61K2039/505 (EP,US);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2021/47] |
Former [2021/15] | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR | Title | German: | GENMUTATIONEN UND KOPIENZAHLÄNDERUNGEN VON EGFR, KRAS UND MET | [2021/15] | English: | GENE MUTATIONS AND COPY NUMBER ALTERATIONS OF EGFR, KRAS AND MET | [2021/15] | French: | MUTATIONS GÉNIQUES ET ALTÉRATIONS DU NOMBRE DE COPIES DE EGFR, KRAS ET MET | [2021/15] | Examination procedure | 14.10.2021 | Amendment by applicant (claims and/or description) | 14.10.2021 | Examination requested [2021/47] | 14.10.2021 | Date on which the examining division has become responsible | 09.06.2023 | Despatch of a communication from the examining division (Time limit: M04) | 19.10.2023 | Reply to a communication from the examining division | Parent application(s) Tooltip | EP15792393.9 / EP3143163 | Fees paid | Renewal fee | 24.11.2020 | Renewal fee patent year 03 | 24.11.2020 | Renewal fee patent year 04 | 24.11.2020 | Renewal fee patent year 05 | 24.11.2020 | Renewal fee patent year 06 | 27.05.2021 | Renewal fee patent year 07 | 27.05.2022 | Renewal fee patent year 08 | 30.05.2023 | Renewal fee patent year 09 | 28.05.2024 | Renewal fee patent year 10 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [X]WO2008112274 (AMGEN INC [US], et al) [X] 1,3,6,9-15 * the whole document *; | [X]WO2010145796 (MERCK PATENT GMBH [DE], et al) [X] 1,3,6,8-11,14,15 * the whole document *; | [X]WO2011028540 (GENENTECH INC [US], et al) [X] 1,3,6,9-11,14,15 * the whole document *; | [X]WO2012131092 (SIGNATURE DIAGNOSTICS AG [DE], et al) [X] 1,3,6,9-15 * the whole document *; | [XP]WO2014182521 (MEDIMMUNE LLC [US], et al) [XP] 1-3,6,9-15 * the whole document *; | [X] - SANDRA MISALE ET AL, "Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer", NATURE, London, (20120613), doi:10.1038/nature11156, ISSN 0028-0836, XP055287051 [X] 1-3,6,9-15 * the whole document * DOI: http://dx.doi.org/10.1038/nature11156 | [X] - F. MOLINARI ET AL, "Increased Detection Sensitivity for KRAS Mutations Enhances the Prediction of Anti-EGFR Monoclonal Antibody Resistance in Metastatic Colorectal Cancer", CLINICAL CANCER RESEARCH, (20110715), vol. 17, no. 14, doi:10.1158/1078-0432.CCR-10-3137, ISSN 1078-0432, pages 4901 - 4914, XP055113596 [X] 1-3,6,9-15 * the whole document * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-10-3137 | [X] - DE ROOCK W ET AL, "Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis", THE LANCET ONCOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 11, no. 8, doi:10.1016/S1470-2045(10)70130-3, ISSN 1470-2045, (20100801), pages 753 - 762, (20100801), XP027598757 [X] 1-3,6,9-15 * the whole document * DOI: http://dx.doi.org/10.1016/S1470-2045(10)70130-3 | [X] - WENDY DE ROOCK ET AL, "KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer", LANCET ONCOLOGY, (20101215), vol. 12, doi:10.1016/S1470-2045(10)70209-6, pages 594 - 603, XP055180339 [X] 1,3,6,9-15 * the whole document * DOI: http://dx.doi.org/10.1016/S1470-2045(10)70209-6 | [I] - FLORENT MOULIERE ET AL, "Circulating cell-free DNA from colorectal cancer patients reveal high KRAS or BRAF mutation load", vol. 6, no. 3, doi:10.1593/TLO.12445, ISSN 1944-7124, (20130601), pages 319 - 328, TRANSLATIONAL ONCOLOGY, NEOPLASIA PRESS, UNITED STATES, URL: http://www.sciencedirect.com/science/article/pii/S1936523313800836, XP002730499 [I] 7,8 * the whole document * DOI: http://dx.doi.org/10.1593/TLO.12445 | [I] - Spindler ET AL, "Quantitative Cell-Free DNA, KRAS, and BRAF Mutations in Plasma from Patients with Metastatic Colorectal Cancer during Treatment with Cetuximab and Irinotecan | Clinical Cancer Research", CLIN CANCER RES., doi:10.1158/1078-0432.CCR-11-0564, (20120215), page 1177, URL: http://clincancerres.aacrjournals.org/content/18/4/1177.full-text.pdf, (20160907), XP055300413 [I] 7,8 * the whole document * DOI: http://dx.doi.org/10.1158/1078-0432.CCR-11-0564 | by applicant | WO2014039556 | - "NCBI", Database accession no. NP _001120972.1 |